GGrantIndex
Sort

23,748 grants matching melanoma

A New Treatment Paradigm for ALK-Driven Cancers Exploiting Oncogene Overdose

$299,009
Jonathan H Schatz · University Of Miami School Of Medicine · R01 · FY2017 · CA

GRNs Guiding Cranial Versus Trunk Neural Crest Formation

$298,943
Marianne Bronner · California Institute Of Technology · P01 · FY2016 · HD

Role of CXCR3 for CD8+ T cells in cancer immunotherapy

$298,935
David W. Mullins · Dartmouth College · R01 · FY2013 · CA

Cancer cell telomere dynamics and responses to perturbations

$298,913
Elizabeth H Blackburn · University Of California, San Francisco · R01 · FY2011 · CA

Multiplexed Bioassay for Checkpoint Inhibitor Autoimmunity

$298,911
Mark J. Mamula · L2 Diagnostics, Llc · R41 · FY2020 · AI

Bifunctional Protein-Polymer Bioconjugates for Localized Melanoma Immunotherapy

$298,864
Wesley Michael Jackson · Valitor, Inc. · R43 · FY2018 · CA

ESTABLISHING THE ROLE OF DEPLOYMENTS IN MELANOMA IN THE MILITARY

$298,862
The University Of Iowa · · FY2021 · Defense Health Agency

IDENTIFICATION AND CONTROL OF CANCER RISK

$298,808
Harvard University (Sch Of Public Hlth) · R01 · FY2000 · CA

Store-operated calcium entry in tumor invasion and metastasis

$298,807
Shengyu Yang · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2018 · CA

P53 inactivation on MDSC development and tumor progression

$298,800
Yan Cui · Lsu Health Sciences Center · R01 · FY2013 · CA

Regulation of PTEN Activity in Cancer Cells

$298,795
University Of Arizona · R01 · FY2002 · CA

Arf6 inhibitors for the treatment of uveal melanoma

$298,731
Alan L Mueller · Navigen, Inc. · R43 · FY2015 · CA

Development of a novel Virus-Like Particle vaccine-based cancer immunotherapy targeting PD-L1.

$298,729
Wataru Akahata · Vlp Therapeutics, Llc · R43 · FY2017 · CA

Fusogenic Membrane Glycoproteins for Cancer Gene Therapy

$298,688
Mayo Clinic · R01 · FY2005 · CA

Fusogenic Membrane Glycoproteins for Cancer Gene Therapy

$298,688
Mayo Clinic · R01 · FY2004 · CA

Epigenetic Effect of the Microenvironment on Stem Cell Plasticity and Function

$298,619
Mary J.c. Hendrix · Lurie Children'S Hospital Of Chicago · R01 · FY2007 · CA

Project 4: Immunovirotherapy

$298,617
Richard G Vile · Mayo Clinic Rochester · P50 · FY2021 · CA

PD-1 Abrogation and Immunity in Melanoma

$298,576
Jeffrey S Weber · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2013 · CA

Understanding resistance in the HER2-HER3 tumor drive

$298,554
Mark M Moasser · University Of California, San Francisco · R01 · FY2015 · CA

Understanding resistance in the HER2-HER3 tumor drive

$298,554
Mark M Moasser · University Of California, San Francisco · R01 · FY2017 · CA

Understanding resistance in the HER2-HER3 tumor drive

$298,554
Mark M Moasser · University Of California, San Francisco · R01 · FY2016 · CA

Role of a novel Notch1 target gene in skin carcinogenesis

$298,542
Anna Mandinova · Massachusetts General Hospital · R01 · FY2014 · CA

Production of Image-Guided Metastatic Melanoma Therapy Radiopharmaceuticals

$298,530
Frances L Johnson · Viewpoint Molecular Targeting, Inc. · R43 · FY2016 · CA

Developement of an alphavirus vaccine for melanoma

$298,527
Gerald P Donovan · Progenics Pharmaceuticals, Inc. · R43 · FY2007 · CA

GCDH Addiction in Melanoma

$298,503
Ze'ev A Ronai · Cedars-Sinai Medical Center · R01 · FY2024 · CA